268 related articles for article (PubMed ID: 23929653)
21. Down-regulation of Rab17 promotes tumourigenic properties of hepatocellular carcinoma cells via Erk pathway.
Qi J; Zhao P; Li F; Guo Y; Cui H; Liu A; Mao H; Zhao Y; Zhang X
Int J Clin Exp Pathol; 2015; 8(5):4963-71. PubMed ID: 26191189
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference.
Xie B; Xing R; Chen P; Gou Y; Li S; Xiao J; Dong J
J Surg Res; 2010 Aug; 162(2):231-8. PubMed ID: 19765730
[TBL] [Abstract][Full Text] [Related]
23. Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma.
Chen CF; Hsu EC; Lin KT; Tu PH; Chang HW; Lin CH; Chen YJ; Gu DL; Lin CH; Wu JY; Chen YT; Hsu MT; Jou YS
Hepatology; 2010 Nov; 52(5):1690-701. PubMed ID: 20799341
[TBL] [Abstract][Full Text] [Related]
24. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
[TBL] [Abstract][Full Text] [Related]
25. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
26. [Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference].
Zhang PH; Tu ZG; Yang MQ; Huang WF; Zou L; Zhou YL
Ai Zheng; 2004 Jun; 23(6):619-25. PubMed ID: 15191658
[TBL] [Abstract][Full Text] [Related]
27. Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma.
Cheng N; Li Y; Han ZG
Hepatology; 2013 May; 57(5):1906-18. PubMed ID: 23258480
[TBL] [Abstract][Full Text] [Related]
28. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
29. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.
Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY
Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo.
Hitomi M; Yokoyama F; Kita Y; Nonomura T; Masaki T; Yoshiji H; Inoue H; Kinekawa F; Kurokohchi K; Uchida N; Watanabe S; Kuriyama S
Int J Oncol; 2005 Mar; 26(3):713-20. PubMed ID: 15703828
[TBL] [Abstract][Full Text] [Related]
31. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
Kuriyama S; Hitomi M; Yoshiji H; Nonomura T; Tsujimoto T; Mitoro A; Akahane T; Ogawa M; Nakai S; Deguchi A; Masaki T; Uchida N
Int J Oncol; 2005 Aug; 27(2):505-11. PubMed ID: 16010434
[TBL] [Abstract][Full Text] [Related]
32. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.
Montero J; Morales A; Llacuna L; Lluis JM; Terrones O; Basañez G; Antonsson B; Prieto J; García-Ruiz C; Colell A; Fernández-Checa JC
Cancer Res; 2008 Jul; 68(13):5246-56. PubMed ID: 18593925
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
36. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
37. CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells.
Xu X; Yamamoto H; Liu G; Ito Y; Ngan CY; Kondo M; Nagano H; Dono K; Sekimoto M; Monden M
Int J Mol Med; 2008 Feb; 21(2):145-52. PubMed ID: 18204780
[TBL] [Abstract][Full Text] [Related]
38. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma.
Xiao Z; Li CH; Chan SL; Xu F; Feng L; Wang Y; Jiang JD; Sung JJ; Cheng CH; Chen Y
Cancer Res; 2014 Nov; 74(21):6236-47. PubMed ID: 25217526
[TBL] [Abstract][Full Text] [Related]
39. Brain-derived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma.
Lam CT; Yang ZF; Lau CK; Tam KH; Fan ST; Poon RT
Clin Cancer Res; 2011 May; 17(10):3123-33. PubMed ID: 21421859
[TBL] [Abstract][Full Text] [Related]
40. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
Satow R; Shitashige M; Kanai Y; Takeshita F; Ojima H; Jigami T; Honda K; Kosuge T; Ochiya T; Hirohashi S; Yamada T
Clin Cancer Res; 2010 May; 16(9):2518-28. PubMed ID: 20388846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
